Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center

Annals of Oncology

Volumn 8, Issue 7, 1997, Pages 685-690

  Janson, E T ^a   Holmberg, L ^a   Stridsberg, M ^a   Eriksson, B ^a   Theodorsson, E ^b   Wilander, E ^a   Oberg K ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Carcinoid tumor; Chromogranin; Prognostic factor; Survival; U 5HIAA

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CHROMOGRANIN A; NEUROPEPTIDE K;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; CARCINOID; CARCINOID SYNDROME; CONTROLLED STUDY; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOID TUMOR; CHROMOGRANIN A; CHROMOGRANINS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROPEPTIDES; PROGNOSIS; SURVIVAL ANALYSIS; TACHYKININS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030807282     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008215730767     Document Type: Article

References (24)

1. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963; 1: 238-9.
2. Norheim I, Öberg K, Theodorsson-Norheim E et al. Malignant carcinoid tumors: An analysis of 103 patients with regard to tumor localization, hormone production and survival. Ann Surg 1987; 206: 115-25.
3. Grahame-Smith DG. The Carcinoid Syndrome. Am J Cardiol 1968; 21: 376-7.
4. Feldman JM and O'Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 1986; 81:41-8.
5. Eriksson B, Arnberg H, Öberg K et al. A polyclonal antiserum against chromogranin A and B - a new sensitive marker for neuroendocrine tumours. Acta Endocrinol 1990; 122: 145-55.
6. Moertel CG, Sauer WG, Dockerty MB et al. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14: 901-12.
7. Godwin JD. Carcinoid tumors. An analysis of 2857 cases. Cancer 1975; 36: 560-9.
8. McDermott EWM, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 1994; 81: 1007-9.
9. Greenberg RS, Baumgarten DA, Clark WS et al. Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors. Cancer 1987; 60: 2476-83.
10. Wilander E, Lundqvist M, Öberg K. Gastrointestinal carcinoid tumours. Progr Histochem Cytochem 1989; 19: 1-85.
11. Öberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983; 309: 129-33.
12. Öberg K, Norheim I, Lundqvist G et al. Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin - alone or in combination with 5-FU. Acta Oncol 1987; 26: 429-32.
13. Janson ET, Rönnblom L, Ahlström H et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: A randomized trial. Ann Oncol 1992; 3: 635-8.
14. Janson ET, Ahlström H, Andersson T et al. Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumors. Eur J Cancer 1992; 28A: 1647-50.
15. Wahlund KG, Edlén B. Simple and rapid determination of 5-hydroxyindole-3-acetic acid in urine by direct injection on a liquid chromatographic column. Clin Chim Acta 1981; 110: 71-6.
16. Theodorsson-Norheim E, Norheim I, Öberg K et al. Neuropeptide K.: A major tachykinin in plasma and tumor tissues from carcinoid patients. Biochem Biophys Res Comm 1985; 131: 77-83.
17. Moertel CG. An odyssey in the land of small tumors. J Clin Oncol 1987; 5: 1503-22.
18. Hajdu SI, Winawer SJ, Myers WPL. Carcinoid tumors. A study of 204 cases. Am J Clin Pathol 1974; 61: 521-8.
19. Pellikka PA, Tajik AJ, Khandheria BK et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993; 87: 1188-96.
20. Lundin L, Norheim I, Landelius J et al. Carcinoid heart disease: Relationship od circulating vasoactive substances to ultrasound detectable abnormalities. Circulation 1988; 77: 264-9.
21. Krenning EP, Bakker WH, Kooij PPM et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phel]-octreotide in man: Metabolism, dosimetry and comparison with [123I-Tyr3]-octreotide. J Nucl Med 1992; 33: 652-8.
22. Westlin JE, Janson ET, Arnberg H et al. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phel]-octreotide. Acta Oncol 1993; 32: 783-6.
23. Eriksson B, Bergström M, Lilja A et al. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. Acta Oncol 1993; 32: 189-96.
24. Hsiao R, Seeger RC, Yu AL et al. Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest 1990; 85: 1555-9.